FDA hands CRL to Merck's chronic cough drug over efficacy questions
The FDA handed a complete response letter (CRL) on Wednesday to Merck for its cough drug gefapixant following an adcomm that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
